Theraclion’s is deploying its scalable robotic platform SONOVEIN® in Europe

Malakoff, 13th December 2021 - THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for noninvasive echotherapy providing consistent, data driven and evidence-based patient care, announces today the opening of new markets in Europe. Two new centers, in Italy and Serbia, will be treating patients with SONOVEIN®. This new milestone is in line with the Theraclion’s growth strategy in the treatment of varicose veins.

In parallel to first steps towards a US FDA approval and first cases in Asia (Hong Kong), Theraclion is now expanding to further markets in Europe.

The adoption in the well established Centro Medico Ippocrate in Parma, Italy and a brand-new vein clinic in Belgrade, Serbia, Theraclion demonstrates the maturity of the SONOVEIN®, “Technological and clinical protocol improvements have made the procedure much faster and our production capabilities now enable us to further deploy the system in Europe,” explains David Caumartin, CEO of Theraclion.

Expansion in Vein Centers of Excellence in Europe

Following its overall strategy Theraclion puts the SONOVEIN into the hands of Key Opinion Leaders in their respective countries:

Prof. Paolo Casoni, is a renowned vascular surgeon, Vice-President of the Italian Phlebology Association and Director of the Centro Medico Ippocrate – Vein Clinic in Parma. The medical-surgical staff is fully dedicated to vascular treatments especially in venous disease and in addition to Parma they will select patients also in other clinics in Milan, Brescia and Salerno.

Dr. Vasic is currently President of the Serbian Society of Angiology, a board member of the European Society of Vascular Medicine, a member of the International Union of Phlebology and the International Union of Angiology.

Both are convinced that SONOVEIN® will radically change vein treatment practice to the better.

“Echotherapy is the first and only office-based extracorporeal vein treatment. Performing “surgery from the outside” opens up completely new ways of treating patients,” explains Pr. Casoni.

About Theraclion

At Theraclion we believe that surgery, as we know it, is outdated. It converts optimistic patients into anxious individuals, brilliant doctors into exhausted system executors and stretches healthcare systems to the limit. We have disrupted this convention by creating extracorporeal treatment platforms. We replace surgery with a robotic treatment from outside the body using High Intensity Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms are currently CE marked in non-invasive treatment of varicose veins with SONOVEIN® and of breast fibroadenomas and thyroid nodules with Echopulse®.

Located in Malakoff, near Paris, our employees live and breath innovation by extensive clinical research and harness artificial intelligence. The market of varicose veins treatment alone requires around 5 million
procedures annually. It is a dynamic market in which we change paradigms by making non-invasive echotherapy the new standard.

For more information, please visit [www.theraclion.com](http://www.theraclion.com) and our patient website [https://echotherapie.com/echotherapy/](https://echotherapie.com/echotherapy/)

Theraclion is listed on Euronext Growth Paris
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29

**Contacts Theraclion**

David Auregan                      Anja Kleber
Chief Operating Officer            VP Marketing, Market Access & Sales Francophonia
[david.auregan@theraclion.com](mailto:david.auregan@theraclion.com)  [anja.kleber@theraclion.com](mailto:anja.kleber@theraclion.com)